Evaluate LIMITED

Evaluate LIMITED is a for-profit, foreign-owned corporate entity based in London, United Kingdom, that is registered to receive federal contract awards from the U.S. government. The company is registered in SAM.gov with a registration expiration date of February 28, 2026. EvaluatePharma, the company's primary offering to federal agencies, is a subscription-based intelligence and analytics platform that delivers market research, competitive analysis, and strategic insights focused on the pharmaceutical industry. This specialized service aligns with the needs of federal agencies tasked with monitoring market competition and conducting regulatory oversight in the healthcare sector.

Evaluate LIMITED has secured two prime federal contract awards, both from the Federal Trade Commission for EvaluatePharma subscriptions. The earlier contract, awarded on September 27, 2024, was valued at $23,000 with an ultimate completion date of September 26, 2025, and was structured as a firm fixed-price definitive contract with no set-aside designation. The more recent prime contract award, dated September 16, 2025, represents a significantly larger three-year subscription valued at $146,365 on a firm fixed-price basis with an ultimate completion date of September 26, 2028, also with no set-aside designation. Additionally, Evaluate LIMITED served as a subcontractor to Research Triangle Institute on a purchase order (PO C000634958) with an award date of March 14, 2025. These contracts demonstrate the company's established role in providing pharmaceutical market intelligence and analytics to support the FTC's antitrust analysis and regulatory enforcement activities.